Grufity logo
Grufity logo
LXRX

LXRX - Lexicon Pharmaceuticals Inc Stock Price, Fair Value and News

$1.95-0.01 (-0.51%)
Market Closed as of 16 Jun 2026, 04:00 pm ET

28/100

LXRX

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

28/100

LXRX

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

LXRX Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

LXRX Price Action

Last 7 days

4.3%

Last 30 days

-12.1%

Last 90 days

21.0%

Trailing 12 Months

192.5%

LXRX RSI Chart

LXRX Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

LXRX Valuation

Market Cap

830.1M

Price/Earnings (Trailing)

-31.82

Price/Sales (Trailing)

11.92

EV/EBITDA

-11.95

Price/Free Cashflow

-21.39

LXRX Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

LXRX Fundamentals

LXRX Revenue

Revenue (TTM)

69.6M

LXRX Earnings

Earnings (TTM)

-26.1M

Earnings Growth (Yr)

95.88%

Earnings Growth (Qtr)

93.28%

LXRX Profitability

EBT Margin

-126.01%

Return on Equity

-12.86%

Return on Assets

-9.71%

Free Cashflow Yield

-4.67%

LXRX Investor Care

Shares Dilution (1Y)

17.58%

Diluted EPS (TTM)

-0.07

LXRX Alerts

  • Big jump in Earnings (Y/Y)
  • Losses in recent quarter

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs(opens in new tab)
Net sales
YearQ1Q2Q3Q4
202669.6M---
202535.8M40.4M45.1M49.8M
20242.3M3.6M5.2M31.1M
2023-597.0K896.0K1.2M
202118.1M12.1M6.2M298.0K
2020320.9M320.3M32.5M24.0M
201947.1M42.9M330.4M322.1M
201899.1M100.8M80.1M63.2M
201788.8M80.8M80.8M91.7M
2016140.7M160.4M187.6M83.3M
201524.4M24.1M24.2M130.0M
20142.1M2.6M2.8M22.9M
20131.1M1.2M1.0M2.2M
20121.6M1.2M1.2M1.1M
20113.9M3.2M2.8M1.8M
2010-8.8M6.8M4.9M
2009---10.7M
Get all data in R, Python etc through our Historical Stock Data APIs(opens in new tab)

About Lexicon Pharmaceuticals Inc

LXRX
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract. The company has strategic collaboration and license agreements with Bristol-Myers Squibb Company, and Genentech, Inc. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.
 CEO
 WEBSITElexpharma.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES135

Lexicon Pharmaceuticals Inc Frequently Asked Questions

LXRX is the stock ticker symbol of Lexicon Pharmaceuticals Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Mon Jun 15 2026, market cap of Lexicon Pharmaceuticals Inc is 834.39 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

As of Mon Jun 15 2026, LXRX's PE ratio (Price to Earnings) is -31.98 and Price to Sales (PS) ratio is 11.98. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. LXRX PE ratio will change depending on the future growth rate expectations of investors.

In the past 10 years, Lexicon Pharmaceuticals Inc has provided -0.174 (multiply by 100 for percentage) rate of return.